Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge
Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge
复制标题
DOI：
10.1099/0022-1317-77-9-2053
复制
发表时间：
1996-09-01
影响因子：
3.8
通讯作者：
Erasmus, B
中科院分区：
文献类型：
--
作者：
Roy, P;Bishop, DHL;Erasmus, B
将从在Sf 9昆虫细胞中生长的单一或双重重组杆状病毒表达载体制备的非洲马疫病毒血清型4（AHSV-4）外衣壳蛋白VP 2或VP 2和VP 5以不同量施用给马，并测量中和抗体应答。6个月后，用强毒AHSV-4攻毒对照和接种疫苗的马，并在攻毒后进行监测。结果表明，两次接种含有VP 2和VP 5的提取物，或单独接种VP 2，剂量为5 μ g VP 2或更高，足以引起对非洲马疫（AHS）的保护。重组VP 2蛋白是一种潜在的候选疫苗，用于马的AHS。
African horsesickness virus serotype 4 (AHSV-4) outer-capsid proteins VP2 or VP2 and VP5, prepared from single or dual recombinant baculovirus expression vectors grown in Sf9 insect cells, were administered in different amounts to horses and the neutralizing antibody responses were measured. Control and vaccinated horses were challenged with virulent AHSV-4 6 months later and monitored post challenge. The results indicated that two inoculations of extracts containing VP2 and VP5, or VP2 alone, in doses of 5 mu g VP2 or more per horse, were sufficient to elicit protection against African horsesickness (AHS) disease, The recombinant VP2 protein is a potential candidate vaccine for AHS in horses.